$48.30 -0.94 (-1.91%)
2/10/2012 4:00 PM

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

CAPS Rating: 2 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Results 1 - 20 of 26 : 1 2 Next »

Recs

0
Member Avatar reddingrunner (93.31) Submitted: 2/1/2012 1:06:04 PM : Outperform Start Price: $48.38 JAZZ Score: -1.21

sabrient systems

Recs

0
Member Avatar srettun (< 20) Submitted: 1/23/2012 9:53:51 PM : Outperform Start Price: $47.00 JAZZ Score: +0.04

breaking out of cup and handle base

Recs

0
Member Avatar ThePoulTrend (80.52) Submitted: 11/11/2011 3:32:45 PM : Outperform Start Price: $39.98 JAZZ Score: +16.22

Xyrem is going to pull in a fortune for Jazz Pharmaceuticals (JAZZ) over the next 3 years.

Xyrem is Sodium Oxybate of which is used to prevent Cataplexy of which is muscle weakness that happens suddenly, and last for short periods of time in patients of who have Narcolepsy a sleep disorder that may cause extreme sleepiness, and uncontrollable urges to sleep during daily activities, + Cataplexy. The facts are more, and more adults, and young adults in their early 20's are getting diagnosed with Narcolepsy, and Cataplexy. With the fact that Xyrem is the only known drug out on the market to help in the treatment of Cataplexy makes it a hot item. Did I mention the Tag Price on this is close to $3000.00 a month, in some cases with patients suffering worse, close to $5000.00

Xyrem is protected by eight patents related to the product's formulation and Jazz Pharmaceuticals' distribution system. These patents expire from 2019 to 2024

Recs

0
Member Avatar guerramo (< 20) Submitted: 10/30/2011 11:28:02 PM : Underperform Start Price: $39.45 JAZZ Score: -16.77

"The FDA said it reviewed Jazz Pharmaceuticals' response ....... the response lacks sufficient corrective actions. The FDA told Jazz its response fails to develop adequate written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to the agency. "You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, injunction. FDA may re-inspect to verify corrective actions have been completed," the FDA said in the letter. (JAZZ)"

Answer yourself this question: where is the answer from Jazz to the FDA? how come it is not on their website or being published in the wire?? the letter was sent by the FDA on 10/11/11, and it's been more than 15 days!! Is management staying quiet until they unload their shares, then leave the retail investor in the hole?!

Recs

0
Member Avatar RallyCry (< 20) Submitted: 9/8/2011 1:02:13 AM : Outperform Start Price: $43.80 JAZZ Score: -2.10

How about trading at 10.5 times 2012 estimates. Nice....

Recs

0
Member Avatar mrindependent (91.56) Submitted: 7/19/2011 5:50:30 PM : Outperform Start Price: $38.65 JAZZ Score: +24.00

value screen

Recs

0
Member Avatar jagad5 (< 20) Submitted: 7/15/2011 12:38:47 PM : Outperform Start Price: $36.95 JAZZ Score: +28.38

revenues are growing 60% per year but PE is only 31, implying <10% growth rate.

Next quarter expect:
REV - $66M
NET - $26M
EPS - $0.63
R^2 = 0.95
Fair value = $100+

Recs

0
Member Avatar Windsun33 (45.99) Submitted: 7/11/2011 11:53:58 AM : Outperform Start Price: $34.66 JAZZ Score: +37.76

Increasing demand for products.

Recs

3
Member Avatar TMFUltraLong (99.99) Submitted: 6/9/2011 3:45:53 AM : Outperform Start Price: $27.05 JAZZ Score: +74.22

It's no secret that the technicals are a bloody mess, but based on the fundamentals alone this company looks like a very probably double. I'm basing this on the fact that Xyrem has been growing considerably faster than anyone had accounted for and Luvox continues to offer a nice supplement to the bottom line. Think about this - even with the earnings beats, Jazz is trading at just 6.6 times 2012 earnings despite revenue growth of 44% in 2011 and 26% in 2012. How about a PEG Ratio of just 0.68 based on 5-year growth estimates? How this company is not trading north of $55 or actively being courted by a larger pharmaceutical name is beyond me. Don't believe me? Believe this guy:

http://www.fool.com/investing/high-growth/2011/05/18/10-mid-caps-to-rule-them-all.aspx?source=itxsitmot0000001&lidx=1

Oh wait, that's me too! Guess I must really like this company huh?

TMFUltraLong

Recs

1
Member Avatar bassettt (66.76) Submitted: 5/30/2011 9:41:47 PM : Outperform Start Price: $29.87 JAZZ Score: +62.00

will be spitting cash all year with nowhere to put it. Look for a special dividend or acquisition late in the year.

Recs

0
Member Avatar EclecticRecluse (76.51) Submitted: 5/5/2011 4:31:17 AM : Outperform Start Price: $28.90 JAZZ Score: +66.92

Relative Pullback Likely Complete, Rise to Resume

Recs

0
Member Avatar rcjansen (33.06) Submitted: 4/13/2011 5:00:13 PM : Outperform Start Price: $34.00 JAZZ Score: +39.26

Increasing sales of existing drugs Xyrem and Luvox with additional products in late stage pipline that should power growth through 2012.

Recs

0
Member Avatar TheBarnacle (88.10) Submitted: 4/7/2011 7:45:29 AM : Underperform Start Price: $33.31 JAZZ Score: -44.30

Hmmmmm.

P/E 45.07
P/S 7.73
P/B 43.88
No ROE
LTD/E 0.81
D/E 1.57

Why is this stock up 196% in one year?

Recs

0
Member Avatar modestus1 (< 20) Submitted: 1/13/2011 9:49:46 PM : Outperform Start Price: $22.63 JAZZ Score: +108.62

great products

Recs

0
Member Avatar tsperbeck (99.48) Submitted: 1/7/2011 1:16:02 PM : Underperform Start Price: $19.51 JAZZ Score: -141.49

Foolish10.

Recs

0
Member Avatar renolori (< 20) Submitted: 12/12/2010 9:32:08 PM : Outperform Start Price: $18.82 JAZZ Score: +149.11

outperform

Recs

0
Member Avatar tenmiles (99.96) Submitted: 11/18/2010 2:51:39 PM : Underperform Start Price: $16.04 JAZZ Score: -189.36

Jazz around $16 making me Dizzy - favors the shorts from here

Recs

0
Member Avatar cbbutton (< 20) Submitted: 7/19/2010 6:03:51 PM : Outperform Start Price: $8.49 JAZZ Score: +441.99

Looming FDA approvial

Recs

4
Member Avatar ross812 (37.60) Submitted: 3/5/2010 8:32:40 AM : Underperform Start Price: $10.15 JAZZ Score: -354.90

Garbage. Garbage. Garbage!!! See what happens if they fail a drug trial!

Recs

0
Member Avatar Positve1 (< 20) Submitted: 12/19/2009 3:26:49 PM : Outperform Start Price: $8.24 JAZZ Score: +464.86

NDA plus buyout potential plus improved bottom line. Looks good as a spec.

Results 1 - 20 of 26 : 1 2 Next »

Featured Broker Partners


Advertisement